- **Barinthus Biotherapeutics plc** and **Clywedog Therapeutics, Inc.** have entered into a definitive **all-stock merger agreement**.  **[1828185_0001104659-25-094754_tm2527141d1_ex99-1.htm:1]** 
- The combined company will be renamed **Clywedog Therapeutics, Inc.** and is expected to trade on NASDAQ under the new ticker symbol **"CLYD"**.  **[1828185_0001104659-25-094754_tm2527141d1_ex99-1.htm:1]** 
- The transaction is projected to close in the **first half of 2026**, with the combined company's cash runway estimated to extend through **2027**.  **[1828185_0001104659-25-094754_tm2527141d1_ex99-1.htm:1]** 
- The combined company will advance a portfolio of three clinical-stage candidates targeting metabolic and autoimmune diseases, with **four key value-driving milestones expected within 18 months** of closing.  **[1828185_0001104659-25-094754_tm2527141d1_ex99-1.htm:1]** 
- Following the Scheme Effective Time and prior to the Merger, Topco (the combined company) will commence a self-tender offer, with the aggregate consideration not exceeding **$27,000,000**.  **[1828185_0001104659-25-094754_tm2527141d1_ex2-1.htm:130]**

Barinthus Biotherapeutics (BRNS)